Rein Therapeutics Inc. (RNTX) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company demonstrates strong financial screening compliance with zero debt and permissible business activities in healthcare. However, it is not included in any major Shariah indices due to its small market capitalization and limited trading history. Overall, while ratios support compliance, index exclusion leads to a non-compliant classification. Investors may consider it for direct holdings pending scholarly consultation.